President Donald Trump’s pick to be the White House’s top drug policy adviser refrained from endorsing a proposed rule to reclassify cannabis from a Schedule I to Schedule III drug under the Controlled Substances Act.That abstention was, in part, because her likely new role prevents her from publicly supporting such a reform.Sara Carter, Trump’s nominee…...
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
